Enzychem Lifesciences Corporation

KOSDAQ 183490.KQ

Enzychem Lifesciences Corporation Cash and Short-Term Investments for the year ending December 31, 2023: USD 105.39 M

Enzychem Lifesciences Corporation Cash and Short-Term Investments is USD 105.39 M for the year ending December 31, 2023, a -30.83% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Enzychem Lifesciences Corporation Cash and Short-Term Investments for the year ending December 31, 2022 was USD 152.36 M, a 92.44% change year over year.
Enzychem Lifesciences Corporation Cash and Short-Term Investments for the year ending December 31, 2021 was USD 79.17 M, a -4.82% change year over year.
Enzychem Lifesciences Corporation Cash and Short-Term Investments for the year ending December 31, 2020 was USD 83.18 M, a 112.45% change year over year.
Enzychem Lifesciences Corporation Cash and Short-Term Investments for the year ending December 31, 2019 was USD 39.15 M, a 25.06% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

KOSDAQ: 183490.KQ

Enzychem Lifesciences Corporation

CEO	Ki-Young Sohn
IPO Date	April 5, 2017
Location	South Korea
Headquarters	aT Center
Employees	122
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Dental Care Pharmaceuticals

Description

Enzychem Lifesciences Corporation, a pharmaceutical company, focuses on the development of oral small molecule therapies for patients with unmet medical needs for oncology, metabolic diseases, and inflammatory diseases in South Korea. It is also developing potential therapies based on EC-18 technology platform to treat chemotherapy-induced neutropenia, chemoradiation therapy-induced oral mucositis, and acute radiation syndrome. The company was founded in 1999 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years